📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy. (2023)

First Author: Sykes RA

Attributed to: MICA: A Developmental Trial of Personalised Medicine for Repurposing Zibotentan, a Selective Endothelin A Receptor Blocker, in Microvascular Angina. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/ehjcvp/pvad025

PubMed Identifier: 37019821

Publication URI: http://europepmc.org/abstract/MED/37019821

Type: Journal Article/Review

Volume: 9

Parent Publication: European heart journal. Cardiovascular pharmacotherapy

Issue: 4